Welcome to the e-CCO Library!

P635 Superior outcomes with early biologic-combination treatment in Crohn’s Disease: Data from an international inception cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Matheeuwsen1, K. Vermeijden1, P. Bossuyt2, L. Pouillon2, F. Baert3, N. de Boer4, M. Duijvestein4, M. Löwenberg1, C. Ponsioen1, W. Bemelman5, G. D’Haens1, K. Gecse1

Created: Thursday, 30 January 2020, 10:12 AM
P635: Assessment of sarcopenia and nutritional status in a cohort of patients with Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Nardone, O.M.(1);de Sire, R.(1);Ponsiglione, A.(2);Rispo, A.(1);Testa, A.(1);Villani, G.(1);Camera, L.(2);Castiglione, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P635: Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to infliximab in patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Guardiola*1,2, L. Rodriguez Alonso1, E. Santacana3, A. Padró4, K. Serra1, N. Padullés3, A. Ruiz-Cerulla1, P. Gilabert1, C. Arajol1, G. Ibañez-Sanz1, B. Camps1, J. Orobitg1, A. Serracarbasa1, L. de la Peña1, A. Berrozpe1, F. Rodriguez Moranta1

Created: Friday, 22 February 2019, 9:41 AM
P635: Enteral nutrition in the treatment of young adults with active Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wall C.*1, Gearry R.2, Day A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P635: Incidence, prevalence, disease phenotype and maximal therapeutic step in Ulcerative Colitis patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem County cohort
Year: 2022
Source: ECCO'22
Authors: Lakatos, L.(1);Gonczi, L.(2);Golovics, P.(3);Pandur, T.(4);David, G.(1);Erdelyi, Z.(1);Szita, I.(1);LakatosPhD, P.L.(2,5);
Created: Friday, 11 February 2022, 3:56 PM
P635: Real-world treatment persistence and associated costs with biologic therapy in patients with inflammatory bowel disease (IBD): Results of a retrospective cohort analysis of 1,149 patients treated in Germany
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Groth1, T. Wilke2, A. Brandes3*, B. Ratsch3, A. Fuchs4, B. Deiters5, B. Bokemeyer6

Created: Thursday, 21 February 2019, 9:14 AM
P635: Risankizumab - real world Israeli data in severe refractory IBD patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bar-Gil Shitrit, A.(1)*;Gil, Y.(2);Israeli, E.(3);Koslowsky, B.(2);Mazuz, B.(2);Israel, I.(2);Goldenberg, R.(2);Ben-Bassat, O.(4);Weisbrud, A.(5);Ledder, O.(6);Zinger, A.(7);Ben Horin, S.(8);Goldin, E.(2);Lahat, A.(8);
Created: Friday, 14 July 2023, 11:12 AM
P636 Changes in peripheral helper T-cell was associated with sustained response to a 12-week EEN therapy in active Crohn’s disease: A pilot study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Guo1,2, W. Gong3, T. Zheng4, W. Li1, M. Fang4, H. Xie4, G. Wang4, G. Gu4

Created: Thursday, 30 January 2020, 10:12 AM
P636: Impact of anti-TNF treatment on extra-intestinal manifestations in patients with inflammatory bowel disease: real-world data in Germany
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Bettenworth*1, W-J. Lee2, R. S. Clark2, S. Rath3, M. Yang4, A. Bensimon4, S. Vavricka5

Created: Friday, 22 February 2019, 9:41 AM
P636: Long-term outcome of anti-tumour necrosis factor treatment in inflammatory bowel disease: A real-life observational study at Østfold Central Hospital, Norway
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Lerang1*, E. Gunther2, M. Henriksen1, L.-P. Jelsness-Jørgensen1,3

Created: Thursday, 21 February 2019, 9:14 AM
P636: Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn's disease: Results from the EVOLVE Expansion study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ferrante, M.(1)*;Christensen, B.(2,3);Bressler, B.(4);Brett, N.(5);Bassel, M.(5);Kamble, P.(6);Adsul, S.(6);Gianchetti, L.(7);Scharl, M.(8);
Created: Friday, 14 July 2023, 11:12 AM
P636: Reproducibility of the main prognostic factors for postoperative recurrence in a cohort of patients with Crohn's disease under anti-Tnf therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Raimundo Fernandes S.*1, Correia L.1, Baldaia C.2, Moura Santos P.2, Rita Gonçalves A.2, Valente A.2, Velosa J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P636: The natural history of COVID-19 in patients with IBD: A nationwide study by the Hellenic Society for the Study of IBD.
Year: 2021
Source: ECCO'21 Virtual
Authors: Bamias, G.(1);Kokkotis, G.(1);Christodoulou, D.(2);Delis, V.(3);Gatopoulou, A.(4);Giouleme, O.(5);Kalantzis, C.(6);Kapsoritakis, A.(7);Karatzas, P.(8);Karmiris, K.(9);Katsanos, K.(2);Kevrekidou, P.(10);Mathou, N.(11);Michalopoulos, G.(12);Michopoulos, S.(13);Papaconstantinou, I.(14);Polymeros, D.(15);Potamianos, S.(7);Poulopoulos, G.(1);Protopappas, A.(16);Soufleris, K.(10);Theodoropoulou, A.(9);Triantafillidis, J.K.(17);Triantafyllou, K.(15);Tsiolakidou, G.(18);Tsironi, E.(19);Tzouvala, M.(20);Viazis, N.(21);Zacharopoulou, E.(20);Zampeli, E.(13);Papatheodoridis, G.(8);Mantzaris, G.J.(21);
Created: Wednesday, 2 June 2021, 4:12 PM
P636: Work disability after 20 years with Inflammatory Bowel Disease - results from the IBSEN study
Year: 2022
Source: ECCO'22
Authors: Lund, C.(1,2);Kristensen, V.A.(1,3);Monstad, I.L.(3);Solberg, I.C.(1);Hovde, Ø.(4);Huppertz-Hauss, G.(5);Henriksen, M.(6);Høie, O.(7);Bernklev, T.(8);Jahnsen, J.(1,9);Moum, B.(1,2);Høivik, M.L.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P637 PERFUSE: A french non-interventional cohort study of infliximab-naive and transitioned patients receiving infliximab biosimilar SB2; An interim analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Bouhnik1, B. Fautrel2, G. Desjeux3, U. Freudensprung4, A. Brigui5, J. Addison6

Created: Thursday, 30 January 2020, 10:12 AM
P637: Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical response
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Dreesen E.*1, Van Stappen T.1, Ballet V.2, Tops S.1, Compernolle G.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P637: High faecal and serum tumour necrosis factor-α levels are associated with non-response to infliximab in patients with ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Meringer1,2,3*, N. Maharshak1,2,3, Y. Ron1,3, H. Yanai1,3,4, S. Cohen-Kedar1,2,3,4, I. Dotan1,2,3,4

Created: Thursday, 21 February 2019, 9:14 AM
P637: Incidence rate and clinical outcome of severe COVID-19 in Inflammatory Bowel Disease patients in a population-based setting
Year: 2021
Source: ECCO'21 Virtual
Authors: Rezazadeh Ardabili, A.(1,2);Creemers, R.H.(2,3);Jonkers, D.M.A.E.(1,2);Romberg-Camps, M.J.L.(3);Pierik, M.J.(1,2);van Bodegraven, A.A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P637: MMP-2 and -8 degraded and citrullinated-vimentin (VICM) correlates to disease activity in inflammatory bowel diseases
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Godskesen1, M. Lindholm2, J. Høg Mortensen2, A. Krag1, T. Manon-Jensen2, M. Karsdal2, J. Kjeldsen1

Created: Friday, 22 February 2019, 9:41 AM
P637: Risks of Development of COVID-19 among Patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Kappelman, M.(1);Zhang, X.(1);Lewis, J.(2);Melmed, G.(3);Siegel, C.(4);Cerciello, E.(5);Dobes, A.(5);Weaver, A.(5);Weisbein, L.(6);Long, M.(7);
Created: Friday, 11 February 2022, 3:56 PM